aTyr Pharma (ATYR) versus The Competition Head-To-Head Comparison

aTyr Pharma (NASDAQ:ATYR) is one of 844 public companies in the “Biotechnology” industry, but how does it weigh in compared to its competitors? We will compare aTyr Pharma to similar companies based on the strength of its risk, institutional ownership, analyst recommendations, earnings, dividends, profitability and valuation.

Profitability

This table compares aTyr Pharma and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
aTyr Pharma	N/A	-95.89%	-69.67%
aTyr Pharma Competitors	-12,359.35%	-203.09%	-30.93%

Institutional and Insider Ownership

61.7% of aTyr Pharma shares are held by institutional investors. Comparatively, 47.9% of shares of all “Biotechnology” companies are held by institutional investors. 5.0% of aTyr Pharma shares are held by company insiders. Comparatively, 13.0% of shares of all “Biotechnology” companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares aTyr Pharma and its competitors top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
aTyr Pharma	$190,000.00	-$74.12 million	-0.25
aTyr Pharma Competitors	$736.67 million	$13.62 million	-14.88

aTyr Pharma’s competitors have higher revenue and earnings than aTyr Pharma. aTyr Pharma is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Volatility and Risk

aTyr Pharma has a beta of 1.04, suggesting that its stock price is 4% more volatile than the S&P 500. Comparatively, aTyr Pharma’s competitors have a beta of 1.14, suggesting that their average stock price is 14% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and price targets for aTyr Pharma and its competitors, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
aTyr Pharma	1	1	1	1	2.50
aTyr Pharma Competitors	9801	15087	45415	1579	2.54

aTyr Pharma presently has a consensus target price of $4.00, suggesting a potential downside of 34.69%. As a group, “Biotechnology” companies have a potential upside of 100.89%. Given aTyr Pharma’s competitors stronger consensus rating and higher probable upside, analysts clearly believe aTyr Pharma has less favorable growth aspects than its competitors.

Summary

aTyr Pharma competitors beat aTyr Pharma on 8 of the 13 factors compared.

About aTyr Pharma

aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.